glp-1- GLP-ONE Activator Bundle and natural appetite control. GLP-1 Updates for Employers: Demand,

Add-On to Metformin A total of 546 adult patients with type 2 diabetes mellitus with inadequate glycemic control (HbA1c 7% and 10%) participated in a 24-week, placebo-controlled trial to evaluate FARXIGA in combination with metformin (NCT00528879)

Suggested use: Recommended serving size is 1 tablet per day

Scientific Reports 4(1):4260

Similar content being viewed by others 1 Introduction Semaglutide (US brand name Ozempic or Wegovy), a Glucagon-like peptide-1 receptor (GLP-1R) agonist containing the active ingredient semaglutide, is approved by the Food and Drug Administration for its potential therapeutic role in obesity and diabetes mellitus (DM) similar to other agonists within the GLP-1R family such as liraglutide